Clinical Trial

A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma(PANKU-Esophagus01)

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This study is a registered phase Ill, randomized, open-label, multicenter study to evaluate the efficacy and safety of BL-B01D1 in patients with recurrent or metastatic esophageal squamous cell carcinoma after failure of PD-1/PD-L1 monoclonal antibody in combination with platinum-based chemotherapy.
Protocol Amendment History 2 changes
notable Primary completion moved earlier: 2026-05 -> 2025-10-17 2026-07-24
minor Completion pushed: 2026-05 -> 2027-06 2026-07-24
Trial Details
NCT Number NCT06304974
Lead Sponsor Sichuan Baili Pharmaceutical Co., Ltd.
Collaborators: Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.
Conditions Esophageal Squamous Cell Carcinoma
Enrollment 497 participants
Start Date 2024-03-19
Primary Completion 2025-10-17 (estimated)
Study Completion 2027-06 (estimated)
Updated on ClinicalTrials.gov 2026-07-23